CN103933086A - Creat/amikacin-containing compound medicine for livestock and fowl - Google Patents
Creat/amikacin-containing compound medicine for livestock and fowl Download PDFInfo
- Publication number
- CN103933086A CN103933086A CN201410170970.6A CN201410170970A CN103933086A CN 103933086 A CN103933086 A CN 103933086A CN 201410170970 A CN201410170970 A CN 201410170970A CN 103933086 A CN103933086 A CN 103933086A
- Authority
- CN
- China
- Prior art keywords
- amikacin
- compound medicine
- drug
- medicine
- herba andrographis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a creat/amikacin-containing compound medicine for livestock and fowl, which is prepared from the following raw materials in parts by weight: 7-30 parts of amikacin and 10-160 parts of creat. The raw materials are evenly mixed and prepared into powder, tablets, oral liquids or granules, and 0.1-7g of the compound medicine is added to every kilo of feed for livestock and fowl for feeding; and the feed with the compound medicine can reverse the drug resistance of bacteria to antibacterial agents, thereby enhancing the treatment effect of the antibacterial agents, greatly lowering the medicine cost and medicine residue, creating higher economic benefit for farmers and ensuring the human food safety.
Description
Technical field
The invention belongs to poultry coli-infection treatment technology field, relate in particular to a kind of poultry compound medicine containing Herba Andrographis and amikacin.
Background technology
Escherichia coli are common conditioned pathogens, also be normal a kind of disease of sending out, its multiple location severe infections such as chicken acute sepsis, peritonitis, hepatitis, pneumonia, enteritis of can formerly having carried out the coffin upon burial, also can secondary or mixed sending out in virosis, to aquaculture, causes huge economic loss.The beta-lactam lopps antibiotic such as amoxicillin, ampicillin, ceftiofur, ceftriaxone, amoxicillin/clavulanate, ampicillin/sulbactam are the conventional important drugs of this disease of control, along with cultivation scale intensive degree is more and more large, medication is more and more spread unchecked, its Resistant strain is more and more many, also more about the report of Drug Resistance of E. coli.Studies confirm that, one of main mechanism of drug resistance is to produce beta-lactamase, especially extended spectrumβ-lactamase (Extended-Spectrum β-lactamase, ESBLs), this enzyme can be more by force and is hydrolyzed rapidly beta-lactam nucleus, makes this class antibiotic lose antibacterial activity.ESBLs is the main enzyme type of beta-lactamase, and it is not only to cephalo three generations and aztreonam drug resistance, and aminoglycoside, quinolones and sulfonamides are to crossing drug resistant, only to carbapenems, a mould alkene class medicaments insensitive.Many documents have reported colibacillary multi-drug resistant and have produced ESBLs and have substantial connection, both at home and abroad to comparatively pay close attention to.The detection, extraction, enzyme that inventor has carried out food animal source pathogenic bacterium ESBLs recently presses down the researchs such as enzyme protection effect to antibiotic percent hydrolysis and sulbactam, Tazobactam Sodium and Chinese medicine; to part ESBLs, colibacillary drug sensitive test shows, its multidrug resistant rate is apparently higher than non-ESBLs bacterial strain.In addition, result also shows to produce ESBLs bacterial strain not only to the serious drug resistance of the third generation cephalosporins such as ceftiofur, and also to multiple antimicrobial drug drug resistance such as fluoroquinolones, aminoglycoside and sulfonamides, fosfomycin etc., is serious multidrug resistant.Inventor is separated to the escherichia coli that tolerate P-levels mycin produces fosA3 drug resistant gene in producing ESBLs bacterial strain, has more strengthened the drug resistance of antibacterial.Colibacillary drug resistance causes raiser's drug cost to increase, and treatment extends the course for the treatment of, and mortality of livestock increases, and to production, brings larger economic loss, and increases poultry drug residue risk.Therefore, in actual production, need a kind of to no matter whether, the escherichia coli of drug resistance can have the medicine of better therapeutical effect badly, and can shorten treatment course for the treatment of, reduce mortality rate, reducing economic loss and reduce drug residue, is that raiser creates higher economic benefit, also ensures that the mankind's is healthy and safe.
Summary of the invention
The technical problem to be solved in the present invention is to provide a kind of poultry compound medicine containing Herba Andrographis and amikacin, it can kill antibacterial quickly, overcome antimicrobial drug treatment due to large, the residual height of weak curative effect, consumption and the high defect of cost that drug resistance problem causes, avoided that simple Chinese medicine sterilizing spectrum is narrow, slow problem sterilizes.
For solving above technical problem, the present invention by the following technical solutions: a kind of poultry compound medicine containing Herba Andrographis and amikacin, is comprised of the raw material of following weight portion: amikacin 7-30 part, Herba Andrographis 10-160 part.
Described compound medicine is prepared into powder, tablet, oral liquid or granule.
The preparation method of described compound medicine is: Herba Andrographis was pulverized to 60 mesh sieves, then mix with pulverous antimicrobial drug, and be prepared into according to a conventional method powder, tablet, oral liquid or granule.
The drug resistance problem existing for current poultry coli-infection, inventor utilizes Guangxi Special Traditional Chinese Medicine Herba Andrographis and antimicrobial drug to form compound medicine.Studies have shown that, in antimicrobial drug, add after Herba Andrographis, can reverse the drug resistance of bacteria medicine, thereby improve the therapeutic effect of antimicrobial drug.According to a conventional method this compound medicine is made to powder, tablet, oral liquid or granule, according to the addition of 0.1-7g principal agent/kg feedstuff, add in animal and fowl fodder and feed, can significantly reduce drug cost and drug residue, for raiser creates higher economic benefit, also guaranteed food safety simultaneously.
The specific embodiment
One, the drug resistance inversion effect research of Herba Andrographis to antimicrobial drug
Antimicrobial drug itself has the colibacillary effect for the treatment of, but has stronger drug resistance owing to producing the escherichia coli of ESBLs drug resistant gene, causes antimicrobial drug not show good therapeutic effect in normal using dosage situation.
In order to verify the drug resistance inversion effect of Herba Andrographis to antimicrobial drug, on 96 orifice plates, adopt microtest tube doubling dilution, first measure antimicrobial drug to producing minimal inhibitory concentration and the subinhibitory concentration of Herba Andrographis to product ESBLs and fosA3 drug resistant gene e. coli strains of the e. coli strains of ESBLs and fosA3 drug resistant gene, then in culture medium, added the Herba Andrographis of subinhibitory concentration to reuse the minimal inhibitory concentration that microtest tube doubling dilution is cultivated mensuration antimicrobial drug; Utilize continuous passage method in the culture medium that is added with same subinhibitory concentration Herba Andrographis and same concentration antimicrobial drug to producing the cultivation of going down to posterity of ESBLs and fosA3 drug resistant gene e. coli strains, until the antimicrobial drug minimal inhibitory concentration observing with go down to posterity before compare and diminish more than 4 times, can be judged as Herba Andrographis has drug resistance inversion effect to antibacterial medical instrument.Result of the test statistics is as shown in table 1:
Table 1 subinhibitory concentration (0.25g/mL) Herba Andrographis goes down to posterity and causes the variation (μ g/mL) of producing ESBLs and fosA3 escherichia coli Western medicine MIC.
As seen from the above table, antimicrobial drug all reduces more than 4 times the colibacillary minimal inhibitory concentration of drug resistance, can judge that Herba Andrographis has drug resistance inversion effect to producing ESBLs and fosA3 drug resistant gene escherichia coli.
Two, the application example of compound medicine of the present invention
Preparation Example 1-embodiment 8 in accordance with the following methods: Herba Andrographis was pulverized after 60 mesh sieves, as basic material, then with pulverous antimicrobial drug by weight ratio put into blender and mix, according to a conventional method, compound medicine is prepared into formulation products.
The formula of table 2 embodiment 1-8 and preparation dosage form
| Numbering | Antimicrobial drug | Herba Andrographis | Dosage form |
| Embodiment 1 | Amikacin 20g | 80g | Powder |
| Embodiment 2 | Amikacin 13g | 10g | Tablet |
| Embodiment 3 | Amikacin 7g | 160g | Oral liquid |
| Embodiment 4 | Amikacin 30g | 110g | Granule |
| Embodiment 5 | Amikacin 15g | 120g | Powder |
| Embodiment 6 | Amikacin 25g | 50g | Tablet |
| Embodiment 7 | Amikacin 10g | 80g | Oral liquid |
| Embodiment 8 | Amikacin 30g | 160g | Granule |
Inventor obtains compound medicine product by above-described embodiment and has carried out following experiment:
1, the efficacy experiment of the compound medicine product of embodiment 1-4 gained to the piglet diarrhea of 42 ages in days
Clinical symptoms: pig farm, Hengxian County, 42 age in days piglets, this swinery after wean is turn-taked, starts to occur diarrhoea, draws watery stools, feces contains indigested feedstuff, pig material feeding but be exactly not grow, indivedual serious diarrhea of pigs dehydrations are dead, do not occur symptoms of emesis, raiser uses multi-medicament, and ideal effect does not all appear in treatment.
Cut open inspection pathological changes: after cuing open inspection, Intestinum Sus domestica wall is poor, especially small intestinal rear end and colon position, intestinal mucosa comes off, and intestinal wall is congested, hemorrhage.
Laboratory diagnosis: get pathologic liver and dye sheet, Gram’s staining, micro-Microscopic observation, the gram negative bacilli of red color visible; Tentatively be judged as bacillus coli.By escherichia coli, cultivate, biochemical test discriminating, judgement Infection in Piglets is bacillus coli, pcr amplification proves and produces ESBLs drug resistant gene and the fosA3 drug resistant gene that has CTX-M type.
Test therapeutic regimen: morbidity swinery is divided 6 groups of administrations, use embodiment 1 according to the addition administration of 1g/kg feedstuff for first group, use embodiment 2 according to the addition administration of 0.5g/kg feedstuff for second group, use embodiment 3 according to the addition administration of 7g/kg feedstuff for the 3rd group, use embodiment 4 according to the addition administration of 1.3g/kg feedstuff for the 4th group; The 5th group with amikacin powder according to the addition administration of 0.3g/kg feedstuff, the 6th group with the thick powder of Herba Andrographis according to the addition administration of 7g/kg feedstuff; Above six groups of therapeutic regimens all continue to use 5 days.
Result of use feedback: first group to the 4th group medication is after 2 days, and swinery is no longer drawn watery stools, feces is shaped, and no longer contains feedstuff in feces, continues to use 3 days swinery recovery from illness; The 5th group of medication is after 2 days, and swinery is still unhealthy, continue to use 3 days, substantially get well, but still draw pasty state feces individually, but drug withdrawal is after 3 days, and recurrence appears in swinery; The 6th group of medication is after 2 days, and swinery, without remarkable improvement, continues to use 3 days, and swinery continues to have loose bowels, and all the other are also more serious individually.Visible, the compound medicine that contains Herba Andrographis is better than folk prescription amikacin and folk prescription Herba Andrographis to swinery curative effect.
2, the efficacy experiment of the compound medicine product of embodiment 5-8 gained to the meat-type duck diarrhoea of 35 ages in days
Clinical symptoms: Guiping, Guangxi duck field, 35 age in days meat-type duck, duck group draws watery stools, has obvious indigested feedstuff in feces.Indivedual serious duck appearance feet gradually of suffering from diarrhoea are soft slowly dead.
Cut open inspection pathological changes: the duck that dies of illness dehydration is more serious, indivedual ducks are still very large, duck liver enlargement, hyperemia, and adularescent film on the liver of part duck, air bag is muddy, and tentative diagnosis is escherichia coli or duck oromeningitis.
Test therapeutic regimen: morbidity duck group divides six groups of administrations, use embodiment 5 according to the addition administration of 2.5g/kg feedstuff for first group, use embodiment 6 according to the addition administration of 1g/kg feedstuff for second group, use embodiment 7 according to the addition administration of 2.5g/kg feedstuff for the 3rd group, use embodiment 8 according to the addition administration of 1.7g/kg feedstuff for the 4th group; The 5th group with amikacin powder according to the addition administration of 0.3g/kg feedstuff, the 6th group with the thick powder of Herba Andrographis according to the addition administration of 4g/kg feedstuff; Above six groups of therapeutic regimens all continue to use 5 days.
Result of use feedback: first group to the 4th group medication is after 3 days, and sick duck is no longer drawn watery stools, feces is shaped, and no longer occurs dead duck, continues to use 2 days, and duck group be almost recovered; The 5th group of medication is after 3 days, duck group DeGrain, much still draw watery stools, contain indigested feedstuff, continue to use 2 days, some improvement a little, but thoroughly not good, rare watery stools still occurs, raiser uses the compound medicine of embodiment 5 gained instead, continue to use 3 days, feces all transfers to normally; The 6th group of medication is after 3 days, and duck does not have too large remarkable improvement, continues to use 2 days, and the duck phenomena of mortality are not still effectively controlled.Visible, the compound medicine that contains Herba Andrographis is better than folk prescription to the curative effect of duck diarrhoea.
Claims (2)
1. containing a poultry compound medicine for Herba Andrographis and amikacin, it is characterized in that, by the raw material of following weight portion, formed: amikacin 7-30 part, Herba Andrographis 10-160 part.
2. the poultry compound medicine containing Herba Andrographis and amikacin according to claim 1, is characterized in that, described compound medicine is prepared into powder, tablet, oral liquid or granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410170970.6A CN103933086A (en) | 2014-04-25 | 2014-04-25 | Creat/amikacin-containing compound medicine for livestock and fowl |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410170970.6A CN103933086A (en) | 2014-04-25 | 2014-04-25 | Creat/amikacin-containing compound medicine for livestock and fowl |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103933086A true CN103933086A (en) | 2014-07-23 |
Family
ID=51181143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410170970.6A Pending CN103933086A (en) | 2014-04-25 | 2014-04-25 | Creat/amikacin-containing compound medicine for livestock and fowl |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103933086A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104435013A (en) * | 2014-11-12 | 2015-03-25 | 华南农业大学 | Pteris multifida and amikacin-containing compound drug for livestock and poultry |
| CN104857128A (en) * | 2015-01-09 | 2015-08-26 | 广西南宁市桃源兽药厂 | Animal composition containing epimedium and amikacin, and preparation method thereof |
| CN106139121A (en) * | 2016-09-21 | 2016-11-23 | 广西大学 | A kind of poultry compound medicine containing Cortex Cinnamomi, Fructus Rosae Laevigatae and colistin |
| CN106177905A (en) * | 2016-08-22 | 2016-12-07 | 广西大学 | A kind of poultry compound medicine containing Radix Glycyrrhizae and colistin |
| CN106265919A (en) * | 2016-09-21 | 2017-01-04 | 广西大学 | A kind of poultry compound medicine containing Radix Glycyrrhizae, Cortex Cinnamomi and amikacin |
| CN106267155A (en) * | 2016-09-21 | 2017-01-04 | 广西大学 | A kind of poultry compound medicine containing Radix Glycyrrhizae, Cortex Cinnamomi and colistin |
| CN106389487A (en) * | 2016-11-24 | 2017-02-15 | 防城港市畜牧站 | Compound pharmaceutical composition used for poultry and capable of lowering medicine side effect |
| CN106420893A (en) * | 2016-08-29 | 2017-02-22 | 广西大学 | Tadehagi triquetrum and amikacin containing compound medicine for livestock and poultry |
-
2014
- 2014-04-25 CN CN201410170970.6A patent/CN103933086A/en active Pending
Non-Patent Citations (1)
| Title |
|---|
| 张国祖 等: "穿心莲水提物与10 种临床常用抗菌药联用的体外抑菌试验", 《中国畜牧兽医》 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104435013A (en) * | 2014-11-12 | 2015-03-25 | 华南农业大学 | Pteris multifida and amikacin-containing compound drug for livestock and poultry |
| CN104857128A (en) * | 2015-01-09 | 2015-08-26 | 广西南宁市桃源兽药厂 | Animal composition containing epimedium and amikacin, and preparation method thereof |
| CN106177905A (en) * | 2016-08-22 | 2016-12-07 | 广西大学 | A kind of poultry compound medicine containing Radix Glycyrrhizae and colistin |
| CN106420893A (en) * | 2016-08-29 | 2017-02-22 | 广西大学 | Tadehagi triquetrum and amikacin containing compound medicine for livestock and poultry |
| CN106139121A (en) * | 2016-09-21 | 2016-11-23 | 广西大学 | A kind of poultry compound medicine containing Cortex Cinnamomi, Fructus Rosae Laevigatae and colistin |
| CN106265919A (en) * | 2016-09-21 | 2017-01-04 | 广西大学 | A kind of poultry compound medicine containing Radix Glycyrrhizae, Cortex Cinnamomi and amikacin |
| CN106267155A (en) * | 2016-09-21 | 2017-01-04 | 广西大学 | A kind of poultry compound medicine containing Radix Glycyrrhizae, Cortex Cinnamomi and colistin |
| CN106389487A (en) * | 2016-11-24 | 2017-02-15 | 防城港市畜牧站 | Compound pharmaceutical composition used for poultry and capable of lowering medicine side effect |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103690952B (en) | The compound medicine for the treatment of poultry coli-infection disease | |
| CN103933086A (en) | Creat/amikacin-containing compound medicine for livestock and fowl | |
| CN103127507A (en) | Holly bark containing compound composition for treating escherichia coli infected diseases of livestock and poultry | |
| CN103989725A (en) | Acalypha australis L. and amikacin containing compound medicine for livestock and poultry | |
| CN103961421A (en) | Compound medicine containing radix paeoniae rubra and mequindox for livestock and poultry | |
| CN103127508B (en) | Herba lycopi containing compound composition for treating escherichia coli infected diseases of livestock and poultry | |
| CN103989727A (en) | Acalypha australis L. and mequindox containing compound medicine for livestock and poultry | |
| CN103961400A (en) | Compound medicine comprising herba lycopi and florfenicol and used for livestock and poultry | |
| CN103977088A (en) | Compound medicine containing radix paeoniae rubrathe and fluoroquinolones antibacterial drug used for livestock and poultry | |
| CN103948656A (en) | Creat/fosfomycin-containing compound medicine for livestock and fowl | |
| CN104306420A (en) | Balsamiferou blumea herb and sulfamonomethoxine sodium containing compound medicine for livestock and poultry | |
| CN103948692A (en) | Red paeonia/amikacin-containing compound medicine for livestock and fowl | |
| CN103301463A (en) | Compound composition containing plumbago zeylanica for treating livestock and poultry escherichia coli infection diseases | |
| CN103933544B (en) | A kind of poultry compound medicine containing Herba Andrographis and colistin | |
| CN103933543B (en) | Utilize the method for Herba Andrographis and colistin treatment poultry coli-infection disease | |
| CN103948677A (en) | Boneset/amoxicillin-containing compound medicine for livestock and fowl | |
| CN104027369A (en) | Plumbago zeylanica and norfloxacin containing compound composition for livestock and poultry | |
| CN103908670B (en) | A kind of compound treating poultry coli-infection disease | |
| CN103961401A (en) | Compound medicine comprising herba lycopi and sulfamonomethoxine sodium and used for livestock and poultry | |
| CN104436160A (en) | Balsamiferou blumea herb and colistin containing compound medicine for livestock and poultry | |
| CN104367601A (en) | Compound medicine containing herba pteridis multifidae and mequindox for livestock and poultry | |
| CN104435013A (en) | Pteris multifida and amikacin-containing compound drug for livestock and poultry | |
| CN104435038A (en) | Balsamiferou blumea herb and mequindox containing compound medicine for livestock and poultry | |
| CN104306422A (en) | Balsamiferou Blumea herb and beta-lactam antibacterial drug containing compound medicine for livestock and poultry | |
| CN104027370A (en) | Plumbago zeylanica and mequindox containing compound composition for livestock and poultry |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140723 |
|
| RJ01 | Rejection of invention patent application after publication |